Dr. Jiang Shan | Cancer Treatment | Best Researcher Award

Dr. Jiang Shan | Cancer Treatment | Best Researcher Award

Dr. Jiang Shan | Cancer Treatment | Harbin Medical University | China

Dr. Jiang Shan, an accomplished radiation oncologist and medical scientist at Harbin Medical University Cancer Hospital, is recognized for his pioneering contributions to nuclear medicine, radiation oncology, and nanomaterial-assisted cancer therapy. Holding a Ph.D. in Nuclear Medicine and Radiation Therapy from Harbin Medical University and a Master’s degree in Medical Dosimetry from John Patrick University, Dr. Jiang combines a deep understanding of clinical oncology with cutting-edge research on tumor biology and targeted therapies. He has served as a staff scientist and researcher in the Department of Radiation Oncology at Harbin Medical University Cancer Hospital, where he focuses on integrating molecular sensing, photothermal therapy, and radiopharmaceuticals for improved cancer diagnostics and treatments. His professional experience also includes international academic exposure as a visiting scholar at the Swedish Cancer Institute (Seattle, USA), City of Hope Medical Center (Duarte, USA), and Fudan Tumor Hospital (Shanghai, China), where he gained valuable insight into global radiotherapy advancements. Dr. Jiang’s research interests center on developing nanotechnology-based drug delivery platforms, investigating radio-resistance mechanisms in differentiated thyroid and breast cancers, and exploring hybrid photothermal–radiation therapy for multidrug-resistant tumors. His research skills encompass advanced cell culture and animal modeling, in vivo tumor imaging, photothermal and radiotherapy experimentation, and bioinformatics-based molecular data analysis. Proficient in computational tools such as GraphPad, Orange, and MS Office, he effectively bridges experimental data with clinical translation.

Professional Profile: ORCID 

Selected Publications 

  1. Jiang, S., Hong, Z., Wu, Q., Rouhan, A., Wang, Z., & Ma, T. (2025). Gadd45B deficiency drives radio-resistance in BRAFV600E-mutated differentiated thyroid cancer by disrupting iodine metabolic genes. Cancers, 17(19), Article 3201. (Citations: 22)

  2. Fu, J., Song, C., Jiang, S., Yang, S., Wu, Q., & Li, B. (2025). Drug delivery platform targeting MMP9 in combination with photothermal therapy to improve tumor chemosensitivity. Advanced Healthcare Materials, 14(5), Article 174. (Citations: 35)

  3. Song, C., Guan, X., Xie, C., Jiang, S., Wu, Q., & Ma, T. (2024). Inhibiting PI3K/AKT/mTOR signaling by metal-organic frameworks for overcoming multiple drug resistance in chemoradiotherapy. Science China Materials, 67(5), 2774–2789. (Citations: 41)

  4. Liu, Z., Jiang, S., Tian, Y., Shang, H., Chen, K., & Cheng, W. (2022). Targeted phototherapy by niobium carbide for mammalian tumor models similar to humans. Frontiers in Oncology, 12, 827171. (Citations: 58)

  5. Jiang, S., Liu, Z., Tian, Y., Zhuang, M., Gao, Y., & Hu, H. (2021). A comprehensive evaluation of ZrC nanoparticle in combined photothermal and radiation therapy for treatment of triple-negative breast cancer. Frontiers in Oncology, 11, 801352. (Citations: 76)

Prof. Dr. Shinhaeng Cho | Nanoparticle Synergy | Best Researcher Award

Prof. Dr. Shinhaeng Cho | Nanoparticle Synergy | Best Researcher Award 

Prof. Dr. Shinhaeng Cho, Chonnam National University Hwasun Hospital, South Korea

Dr. Shin-Haeng Cho is a Clinical Assistant Professor in the Department of Radiation Oncology at Chonnam National University Hospital, South Korea. With a strong background in medical physics, he previously served as a Medical Physics Fellow and Academy Member at the Proton Therapy Center of the National Cancer Center, South Korea. Dr. Cho earned his Ph.D. in Solid State Physics and Medical Physics from Korea University, where he also completed his Master’s and Bachelor’s degrees in Physics. His expertise spans radiation treatment planning, proton therapy, dosimetric system development, and dose enhancement research using nanoparticles. He has contributed to advancements in radiation dosimetry, quality assurance, and tumor treatment techniques, including IMRT, VMAT, Tomotherapy, and 3D-HDR brachytherapy. Additionally, Dr. Cho has conducted research on solar cell efficiency improvements using localized surface plasmon resonance and semiconductor crystal growth for radiation detectors. His extensive clinical and research experience underscores his dedication to innovation in radiation oncology and medical physics.

Professional Profile:

ORCID

Suitability for Best Researcher Award 

Dr. Shin-Haeng Cho is a highly qualified researcher with a strong background in radiation oncology, medical physics, and solid-state physics, making him a compelling candidate for the Best Researcher Award. Below is an evaluation of his suitability based on key criteria

🎓 Education

📌 Philosophy of Doctor (Ph.D.) in Solid State Physics and Medical Physics (2008.09 – 2015.02)
🔹 Graduate School of Korea University, South Korea

📌 Master’s Degree in Solid State Physics (2006.03 – 2008.08)
🔹 Graduate School of Korea University, South Korea

📌 Bachelor of Science (B.Sc.) in Physics (1999.03 – 2006.02)
🔹 Korea University, South Korea

🏥 Work Experience

📌 Clinical Assistant Professor (2019.03 – Present)
🔹 Department of Radiation Oncology, Chonnam National University Hospital, South Korea

📌 Medical Physics Fellow (2018.03 – 2019.02)
🔹 Proton Therapy Center, National Cancer Center, South Korea
🔹 Division of Medical Physics

📌 Medical Physics Academy (2016.03 – 2018.02)
🔹 Proton Therapy Center, National Cancer Center, South Korea
🔹 Division of Medical Physics

📌 Research Professor (2015.03 – 2016.02)
🔹 Department of Radiologic Science, Korea University, South Korea

🏆 Achievements & Research Interests

📌 Radiation Oncology & Medical Physics
🔹 Development of Dosimetric Systems for Proton & Photon Beams
🔹 Patient Treatment Planning & Quality Assurance (Proton, IMRT, Tomotherapy, 3D Therapy)
🔹 Dose Measurement & Evaluation in Proton Therapy
🔹 Study on Dose Enhancement for Tumor Cells using Nanoparticles

📌 Semiconductor & Energy Research
🔹 Solar Cell Efficiency Enhancement using Localized Surface Plasmon Resonance (LSPR) with Gold Nanoparticles
🔹 Development of Solar Cells using Polycrystalline Semiconductors
🔹 Crystal Growth of Cd-based II-VI Compounds (CdTe, CdZnTe, CdMnTe, CdTeSe) & Other Materials (InI, TlBr, HgI₂) for Radiation Detectors

🎖 Awards & Honors

🏅 Recognized for Contributions in Radiation Oncology & Medical Physics
🏅 Contributions to Proton Therapy & Radiation Treatment Techniques
🏅 Innovations in Dosimetry & Semiconductor-based Radiation Detectors

Publication Top Notes:

Preliminary Investigation of a Cd0.9Zn0.1Te Detector for Small-Field Dosimetry Applications Using Therapeutic MV Beams

Radiation Hardness Analysis of Inorganic Scintillators Irradiated by a 6 MeV Electron Beam

Dosimetric Analysis of Lung Stereotactic Body Radiotherapy Using Halcyon Linear Accelerator

Performance Comparison of CdTe:Na, CdTe:As, and CdTe:P Single Crystals for Solar Cell Applications

Blood Lymphocytes as a Prognostic Factor for Stage III Non-small Cell Lung Cancer with Concurrent Chemoradiation

Dr. Dong Hyun Kim | Radiation oncology Award | Best Researcher Award

Dr. Dong Hyun Kim | Radiation oncology Award | Best Researcher Award

Dr. Dong Hyun Kim, Seoul National University College of Medicine, South Korea

Dong Hyun Kim, born on April 16, 1993, in South Korea, is a clinical researcher and physician specializing in clinical oncology, hematologic malignancy, and translational medicine. He is currently an external clinical researcher in the Division of Hemato-Oncology at Seoul National University Hospital. Dr. Kim earned his Bachelor of Medicine from Seoul National University College of Medicine in 2019, followed by a Master of Medical Science in Translational Medicine, expected in 2024. He has held positions as an intern and resident doctor in internal medicine at Seoul National University Hospital. Dr. Kim’s research has garnered numerous honors, including the Best Oral Presentation Awards at ICBMT 2022 and ICKSH 2024, as well as the prestigious Presidential Oral Presentation at JSMO 2024.

Professional Profile:

ORCID

SCOPUS

Summary of Suitability for Best Researcher Award: Dong Hyun Kim

Research Excellence: Dong Hyun Kim has demonstrated exceptional contributions to the fields of Clinical Oncology and
Hematologic Malignancy, focusing on translational medicine. His publication record showcases a robust output of 37
articles, with significant works in high-impact journals such as Cells, British Journal of Haematology, and Scientific Reports.
His research spans critical topics, including tumor microenvironments, therapeutic strategies, and the role of artificial
intelligence in oncology

Education:

🎓 Seoul National University College of Medicine, Seoul, Korea

  • Bachelor of Medicine (2015 ~ 2019)
  • Master of Medical Science, Department of Translational Medicine (2022 ~ 2024)

Professional Experience:

🏥 Seoul National University Hospital

  • Intern (2019 ~ 2020)
  • Resident Doctor, Department of Internal Medicine (2020 ~ 2023)
  • External Clinical Researcher, Division of Hemato-Oncology (2023 ~ Present)

Honors & Awards 🏅:

  • Best Oral Presentation Award, ICBMT 2022
  • Presidential Oral Presentation, JSMO 2024
  • Best Oral Presentation Award, ICKSH 2024

Publication top Notes:

Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation

Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome

Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies in Korea

Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study

Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma